Esperion Therapeutics Inc. (NASDAQ:ESPR) shares were up 3.1% on Tuesday . The company traded as high as $11.12 and last traded at $11.00, with a volume of 117,094 shares traded. The stock had previously closed at $10.67.

A number of research analysts have weighed in on ESPR shares. JMP Securities reiterated a “buy” rating and set a $67.00 target price on shares of Esperion Therapeutics in a report on Thursday, June 16th. Citigroup Inc. reiterated a “buy” rating and set a $22.00 target price (down previously from $36.00) on shares of Esperion Therapeutics in a report on Wednesday, June 29th. Lake Street Capital reduced their target price on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, June 29th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 target price (down previously from $77.00) on shares of Esperion Therapeutics in a report on Wednesday, June 29th. Finally, Vetr downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 target price on the stock. in a report on Monday, July 18th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. Esperion Therapeutics has an average rating of “Hold” and an average price target of $24.40.

The stock’s 50-day moving average is $10.97 and its 200-day moving average is $14.76. The firm’s market cap is $244.44 million.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. During the same quarter in the previous year, the business earned ($0.55) EPS. Equities analysts anticipate that Esperion Therapeutics Inc. will post ($3.36) earnings per share for the current fiscal year.

In related news, Director Mark E. Mcgovern bought 5,000 shares of Esperion Therapeutics stock in a transaction dated Wednesday, July 6th. The shares were acquired at an average cost of $10.00 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now owns 600 shares in the company, valued at approximately $6,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.